Doxorubicin affects the cardiac muscarinic system in the rat
During the study on the mechanism of doxorubicin-induced cardiotoxicity, we observed that a long incubation (4 hr) with doxorubicin reduced the maximal negative inotropic effects of a muscarinic receptor agonist, carbachol. The mechanism responsible for this doxorubicin-induced reduction of the efficacy of carbachol was examined in isolated guinea pig hearts. In isolated left atrial muscle preparations, 1 hr incubation with 100 microM doxorubicin caused a parallel right-ward shift of the concentration-response curves for carbachol, but a longer (4 hr) incubation with this agent (30, 100 or 200 microM), caused a significant reduction of the magnitude of the negative inotropic effect of carbachol in addition to the concentration-dependent parallel right-ward shift. The 4-hr incubation with these concentrations of doxorubicin also reduced the maximal negative inotropic effect of an adenosine A1 receptor agonist, R-phenylisopropyl adenosine (R-PIA), without affecting the potency of this agonist. Doxorubicin (1 to 100 microM) reduced [3H]quinuclidinyl benzilate (QNB) binding in a concentration dependent manner, but failed to alter [3HIR-PIA binding. The decrease in the magnitude of the maximal negative inotropic effect by doxorubicin was caused by changes in the muscarinic system at steps common to the transduction of muscarinic and adenosine A1 receptor mechanisms.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2001 |
|---|---|
| Erschienen: |
2001 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
The Journal of veterinary medical science - 63(2001), 12 vom: 17. Dez., Seite 1315-22 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chugun, A [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 20.06.2002 Date Revised 05.06.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM116784180 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM116784180 | ||
| 003 | DE-627 | ||
| 005 | 20231222175057.0 | ||
| 007 | tu | ||
| 008 | 231222s2001 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0390.xml |
| 035 | |a (DE-627)NLM116784180 | ||
| 035 | |a (NLM)11789610 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chugun, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Doxorubicin affects the cardiac muscarinic system in the rat |
| 264 | 1 | |c 2001 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 20.06.2002 | ||
| 500 | |a Date Revised 05.06.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a During the study on the mechanism of doxorubicin-induced cardiotoxicity, we observed that a long incubation (4 hr) with doxorubicin reduced the maximal negative inotropic effects of a muscarinic receptor agonist, carbachol. The mechanism responsible for this doxorubicin-induced reduction of the efficacy of carbachol was examined in isolated guinea pig hearts. In isolated left atrial muscle preparations, 1 hr incubation with 100 microM doxorubicin caused a parallel right-ward shift of the concentration-response curves for carbachol, but a longer (4 hr) incubation with this agent (30, 100 or 200 microM), caused a significant reduction of the magnitude of the negative inotropic effect of carbachol in addition to the concentration-dependent parallel right-ward shift. The 4-hr incubation with these concentrations of doxorubicin also reduced the maximal negative inotropic effect of an adenosine A1 receptor agonist, R-phenylisopropyl adenosine (R-PIA), without affecting the potency of this agonist. Doxorubicin (1 to 100 microM) reduced [3H]quinuclidinyl benzilate (QNB) binding in a concentration dependent manner, but failed to alter [3HIR-PIA binding. The decrease in the magnitude of the maximal negative inotropic effect by doxorubicin was caused by changes in the muscarinic system at steps common to the transduction of muscarinic and adenosine A1 receptor mechanisms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Cardiotonic Agents |2 NLM | |
| 650 | 7 | |a Muscarinic Antagonists |2 NLM | |
| 650 | 7 | |a Purinergic P1 Receptor Agonists |2 NLM | |
| 650 | 7 | |a Receptors, Muscarinic |2 NLM | |
| 650 | 7 | |a Vasodilator Agents |2 NLM | |
| 650 | 7 | |a N-(1-methyl-2-phenylethyl)adenosine |2 NLM | |
| 650 | 7 | |a 20125-40-0 |2 NLM | |
| 650 | 7 | |a Quinuclidinyl Benzilate |2 NLM | |
| 650 | 7 | |a 6581-06-2 |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Carbachol |2 NLM | |
| 650 | 7 | |a 8Y164V895Y |2 NLM | |
| 650 | 7 | |a Adenosine |2 NLM | |
| 650 | 7 | |a K72T3FS567 |2 NLM | |
| 700 | 1 | |a Uchide, T |e verfasserin |4 aut | |
| 700 | 1 | |a Temma, K |e verfasserin |4 aut | |
| 700 | 1 | |a Kennedy, R H |e verfasserin |4 aut | |
| 700 | 1 | |a Klimberg, S V |e verfasserin |4 aut | |
| 700 | 1 | |a Hara, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Sasaki, T |e verfasserin |4 aut | |
| 700 | 1 | |a Akera, T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of veterinary medical science |d 1997 |g 63(2001), 12 vom: 17. Dez., Seite 1315-22 |w (DE-627)NLM012627488 |x 1347-7439 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2001 |g number:12 |g day:17 |g month:12 |g pages:1315-22 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2001 |e 12 |b 17 |c 12 |h 1315-22 | ||